New And Special Drugs
-
Redemplo (Plozasiran) – FCS | HongKong DengYue Medicine
-
Yizekang (Izalontamab Brengitecan) – NPC/ESCC | HongKong DengYue Medicine
-
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
-
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
-
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
-
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
-
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
-
Foundayo(Orforglipron) – Obesity/Overweight | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
Insulin Sudelidec Approved for Type 2 Diabetes in China: A New Chinese Innovation in the Long-Acting Basal Insulin Market
Insulin Sudelidec approved for type 2 diabetes in China following NMPA approval for adults with type 2 diabetes. Key Phase III studies demonstrated comparable glucose-lowering
Common Drugs for Prostate Cancer: A Complete Guide to Hormone Therapy, Targeted Therapy & Chemotherapy
Common drugs for prostate cancer include androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), PARP inhibitors, chemotherapy, PSMA-targeted radioligand therapy, immunotherapy, and bone-targeted therapies.
Plozasiran Now Available in China: A Once-Every-3-Month siRNA Therapy for Familial Chylomicronemia Syndrome (FCS)
Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted siRNA therapy to help lower triglyceride (TG) levels in adults
Ciprocopan Approved in China as the World’s First Once-Daily Oral CFB Inhibitor for PNH
Ciprocopan approved in China as the world’s first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal
Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy
Oveporexton approved first in China, becoming the world’s first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying
Gene Therapy for Beta Thalassemia: Can CRISPR and Gene Addition Achieve Transfusion Independence?
For patients living with transfusion-dependent beta thalassemia (TDT), lifelong blood transfusions have long been the standard of care. While effective in maintaining hemoglobin levels, this
The First Approved ADC for Esophageal Squamous Cell Carcinoma (ESCC): How Izalontamab Brengitecan Is Transforming Treatment
Izalontamab Brengitecan is the first approved ADC for esophageal squamous cell carcinoma (ESCC) worldwide. It is also the world’s first approved EGFR×HER3 bispecific antibody-drug conjugate
Complete Lung Cancer Drugs List (2026 Update)
Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Thanks to advances
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
